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Abstract
Background: Cancer services are inaccessible in many low-income countries, and few published examples describe
oncology programs within the public sector. In 2011, the Rwanda Ministry of Health (RMOH) established Butaro Cancer
Center of Excellence (BCCOE) to expand cancer services nationally. In hopes of informing cancer care delivery in similar
settings, we describe program-level experience implementing BCCOE, patient characteristics, and challenges
encountered.
Methods: Butaro Cancer Center of Excellence was founded on diverse partnerships that emphasize capacity building.
Services available include pathology-based diagnosis, basic imaging, chemotherapy, surgery, referral for radiotherapy,
palliative care and socioeconomic access supports. Retrospective review of electronic medical records (EMR) of patients
enrolled between July 1, 2012 and June 30, 2014 was conducted, supplemented by manual review of paper charts and
programmatic records.
Results: In the program’s first 2 years, 2326 patients presented for cancer-related care. Of these, 70.5 % were female,
4.3 % children, and 74.3 % on public health insurance. In the first year, 66.3 % (n = 1144) were diagnosed with cancer.
Leading adult diagnoses were breast, cervical, and skin cancer. Among children, nephroblastoma, acute lymphoblastic
leukemia, and Hodgkin lymphoma were predominant. As of June 30, 2013, 95 cancer patients had died. Challenges
encountered include documentation gaps and staff shortages.
Conclusion: Butaro Cancer Center of Excellence demonstrates that complex cancer care can be delivered in the most
resource-constrained settings, accessible to vulnerable patients. Key attributes that have made BCCOE possible
are: meaningful North–south partnerships, innovative task- and infrastructure-shifting, RMOH leadership, and an
equity-driven agenda. Going forward, we will apply our experiences and lessons learned to further strengthen
BCCOE, and employ the developed EMR system as a valuable platform to assess long-term clinical outcomes and
improve care.
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Background
As cancer-related mortality rapidly outpaces the capacity
of developing-world healthcare systems, global health dis-
course has increasingly encompassed cancer care [1, 2]. In
2008, cervical cancer and childbirth mortality were com-
parable [3], and in 2012, the 5.3 million cancer deaths
worldwide exceeded those caused by HIV/AIDS, tubercu-
losis, and malaria combined [1]. Yet, while low- and
middle-income countries (LMICs) account for 80 % of
disability-adjusted life-years lost to cancer, only 5 % of on-
cology resources are spent in those countries [2, 4]. Par-
ticularly in LMICs, cancer services are inaccessible for
most patients, with existing programs located primarily
in urban areas or the private sector and focusing on se-
lect cancers [4, 5]. Perhaps with the exception of the
AMPATH-Oncology consortium in Kenya [6], models of
oncology programs embedded within the public sector and
serving rural poor patients are lacking. Furthermore, while
general principles in cancer service delivery in resource-
constrained settings have been described [4, 5, 7, 8], few
groups outline program-level implementation of oncology
services.
Rwanda has greatly improved the health of its 11 mil-
lion citizens since the catastrophic 1994 genocide [9].
Yet cancer care was extremely limited as recently as
2012, with no oncologist, only one hematopathologist,
and three clinical pathologists based in the country. At
the time, services were available at only one district hos-
pital and three urban-based national referral hospitals.
In 2011 driven by its strong equity agenda and having ini-
tiated impressive cervical cancer prevention efforts [10],
Rwanda’s Ministry of Health (RMOH) invited Partners In
Health (PIH) and Dana-Farber/Brigham and Women’s
Cancer Center (DFBWCC) to partner in expanding cancer
care nationally, targeting poor, rural-based patients. In July
2012, the Butaro Cancer Center of Excellence (BCCOE), a
public rural-based facility, was inaugurated by former US
President Bill Clinton and the Honorable Minister of
Health, Dr. Agnes Binagwaho. Here, we report program-
level description of implementing BCCOE, its preliminary
impact and challenges faced in order to share lessons and
inform service delivery in similar settings.
Methods: key components to delivering accessible
cancer services in a resource-constrained setting
Partnerships
Butaro Cancer Center of Excellence was founded on di-
verse, long-term partnerships [7, 8]. Spearheading the ini-
tiative, the RMOH set national priorities and coordinated
collaborations. RMOH also provided infrastructure, staff
(recruitment of nurses and junior doctors along with salary
support for most of them) and non-specialized consum-
ables complementary to oncology services (such as pain
medications and intravenous fluids). PIH, an international
non-governmental organization with a mandate to deliver
healthcare to the most vulnerable communities and exten-
sive experience working in resource-constrained settings
[11], was initially invited by RMOH in 2005 to help ex-
pand HIV services to communities in a rural district in the
Eastern province. This partnership grew over time to ad-
dress evolving needs including those in primary care, med-
ical education and specialty-related care such as cancer. In
addition to bringing this implementation experience to
cancer care, PIH brought on board a network of partners
that availed technical expertise in oncology and pathology,
funding to support salary for selected staff (such as Rwan-
dan internist and pediatrician), procurement of specialized
oncology medications and supplies, pathology equip-
ment and reagents as well as relationships to defray
costs (through procurement networks, volunteer clini-
cians). These partners, including Harvard Medical School,
DFBWCC, Jeff Gordon Children’s Foundation, The Breast
Cancer Research Foundation, LIVESTRONG, and Glax-
oSmithKline, are diverse in scope and committed to long
term partnerships.
Setting and infrastructure
Butaro Cancer Center of Excellence is housed within
Butaro hospital, a rural district hospital in Burera district
(which is home to 321,000 people) located in northern
Rwanda approximately 93 km (and approximately 2.5 h
drive) from the capital city. The hospital was built as a
joint venture between RMOH, PIH, and Clinton Health
Access Initiative. Upon its inauguration in January 2011,
the hospital had 152 beds and departments in emergency,
general medicine, pediatrics, surgery, maternity, two oper-
ating theatres and a neonatal intensive care unit. As of
June 2012, the hospital had 160 employees (including 67
medical and 30 paramedical). The state-of-the-art design
and record for outstanding health achievements in Burera
District [12] made Butaro hospital suitable for a model on-
cology program. A 27-bed cancer ward was converted for
inpatient care, and a weekly cancer outpatient clinic
was integrated into the non-communicable diseases
clinic roster.
Personnel and training
All doctors and nurses at BCCOE received foundational
didactic training through the national baseline cancer
training, a 5-day didactic program - developed by part-
ners including RMOH, PIH, DFBWCC – that covers
general principles in cancer epidemiology, diagnosis,
treatment, and documentation. Selected nurses addition-
ally underwent an 8-week practicum-based longitudinal
chemotherapy mixing and administration course led by
visiting DFBWCC oncology specialty nurses. These
trainings have facilitated long-term capacity building so
that as of December 2014, 270 clinicians have received
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national baseline cancer training, and 36 nurses received
the longitudinal training. Furthermore, three BCCOE
Rwandan nurses have been recognized as national expert
trainers, one of whom co-leads BCCOE-based longitu-
dinal training offered to nurses from the National Refer-
ral Hospital of Kigali (CHUK).
Clinical services
Upon its opening, BCCOE provided histopathology-based
diagnosis [13], X-ray and ultrasound imaging, chemother-
apy, selected surgical procedures, palliative care and socio-
economic supports [14] delivered by a multidisciplinary
team (Table 1). Patients requiring radiotherapy were re-
ferred to Mulago Hospital in Uganda. With no oncology
specialists on-site, care was delivered through task-shifting
and structured twinning, and long-term collaboration
between BCCOE and DFBWCC [7, 8]. Generalist physi-
cians prescribed chemotherapy and performed biopsies
(including breast core-needle and bone marrow) while
nurses mixed and administered chemotherapy. Clinicians
followed standardized protocols and consulted teams of
DFBWCC-based experts through weekly ‘tumor board-
like’ conference calls and frequent emails.
Treatment protocols
Care was standardized using protocols adapted to avail-
able resources and for non-oncologist clinicians [7, 8]. Led
by RMOH and supported by BCCOE staff, protocols were
drafted by international oncology experts and reviewed by
the national Non-communicable Diseases (NCD) tech-
nical working group on an on-going basis. Given Rwanda’s
current lack of a radiotherapy center, treatment maxi-
mized outcomes without radiotherapy. The methodology
for development and the initial vetting of protocols oc-
curred at a conference held in Kigali, attended by cancer
experts from France, USA, South Africa, and Senegal.
The first national cancer protocols were endorsed in
June 2012 (Table 2).
Socioeconomic supports and access
Complementing the medical services available, socioeco-
nomic supports such as food packages and transport
vouchers were critical for vulnerable patients (who were
identified using standardized socioeconomic and clinical
criteria). Additionally, given their prohibitive costs for
the vast majority of patients, chemotherapy, pathology
testing, and referral to Uganda for radiotherapy were
free for all presenting patients and covered by funding
from grants, foundations, and private donations. For all
other hospital-related costs, most patients paid 10 %,
with the remainder covered by the national community-
based health insurance scheme, Mutuelles de Sante
(Mutuelles).
Table 1 Staffing at BCCOE
Initial projectionsa Dec 2012 Dec 2013 Dec 2014
Clinical Physicians
Internists 1 1 2 2
Pediatricians 1 1 1 1
General Practitioners 1 1 2 2
General Surgeonb 0.5 0.5 0.5 0.5
OB/GYNb 0.5 0.5 0.5
Nurses
Inpatient 7 7 13 22
Outpatientc 2 2 2 3
Care Coordinator 1 1 1 1
Histopathology Technicians - 2 2 4
Nutritionist - 0 0 1
Social Worker - 0 0 1
Programmatic Program Director 1 1 1 1
Program Manager 1 1 1 1
Administrative Assistant - 0 1 1
Research Assistant - 0 1 1
Data Officer - 0 1 1
aInitial projections based upon MOH estimates for 27-bed unit and 25 % annual increase in patient population
b provide care for cancer and non-cancer patients
cOutpatient nurses shared with the NCD clinic
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Procurement
A formulary list was generated from standardized proto-
cols. Most medications were off-patent and included in
the World Health Organization’s essential medicines list.
This list also included supplies such as infusion pumps
and personal protective equipment. Procurement planning
transitioned from ad hoc purchases before 2012 for the few
cancer patients to stock orders made every 6–12 months
by 2014. During the first year, consumption was tracked in-
tensively with monthly manual stock counts and projec-
tions based on patient volume. These consumption data
were reviewed quarterly, and orders made for anticipated
stock outs within 6 months. Available drugs and consum-
ables were procured through the public supply chain while
PIH obtained the remainder using funding and DFBWCC
donations. The above was performed by a PIH-employed
pharmacist, working closely with and capacitating Butaro
Hospital pharmacist, pharmacy technicians and relevant
clinical program managers.
Electronic Medical Records (EMR) system
An oncology-specific EMR system was built on an open-
source OpenMRS platform, borrowing principles from
HIV medical record systems [15, 16]. The database was
devised to run off local servers, enabling work during
internet interruptions. With the exception of chemother-
apy ordering performed by clinicians, data entry of
demographic data and clinical events was conducted by
a dedicated data officer who had 2 years post-secondary
school training. A team of a systems analyst, software
developers, data officer, program managers, and clini-
cians developed and implemented this oncology-focused
EMR system.
Ethics
Data related to human subjects presented in this
manuscript is covered under a study protocol approved
by Institutional Review Boards in Rwanda (National
Health Research Council and Rwanda National Ethics
Committee) and USA (Partners Human Research
Committee). Given the retrospective design of this
study and the use of de-identified data for analysis, in-
formed consent was not required by respective Institu-
tional Review Boards.
Results: early findings, challenges faced and
lessons learned
Impact
Between July 1, 2012 and June 30, 2014, 2326 patients pre-
sented to BCCOE for cancer-related evaluation or care.
This is in contrast to 21 patients seen at Butaro hospital
for cancer-related evaluation and care in the preceding
12 month period. Of these 2326 patients, 1640 (70.5 %)
were female. Mean age was 43 years (standard deviation,
SD, 19.8) and 270 (11.6 %) were children younger than
18 years of age (Table 3).
The total number of yearly outpatient visits at Butaro
hospital increased from 17,895 in 2011 to 20,235 in the
program’s first year. During this period, the proportion
of cancer-related outpatient visits also rose from 0.5 to
16 %. The increase in cancer-related hospital admissions
was even more pronounced with 41 % of 6583 admis-
sions between July 1, 2013 and June 30, 2014 being
cancer-related (Butaro Hospital Health Management In-
formation System data, unpublished).
Of the 1144 patients who presented during BCCOE’s
first year (July 1, 2012 to June 30, 2013), 759 (66.3 %)
were diagnosed with cancer (Table 3). Of these, 519
(68.4 %) were female and 102 (13.3 %) children. Fifty-
seven (7.5 %) were HIV-positive by self-report and 150
(19.8 %) had a smoking history. A high proportion (461,
60.7 %) presented with good functional status ECOG of
≤2 [17]. Five hundred and sixty-four patients (74.3 % of
cancer patients, or 98.4 % of those with documented in-
surance status) were on Mutuelles. Sixty-seven patients
(8.8 %) resided in Burera District and 11 (1.5 %) in
neighboring countries. Five hundred and forty-nine
(72.3 %) were referred from district and national referral
hospitals.
Pathology documentation was available for 562 patients
(49.1 % of all patients presenting during BCCOE’s first year,
or 74.0 % of patients diagnosed with cancer). As of June 30,
Table 2 Outline of Rwanda national cancer protocols, using
breast cancer as an example
Each protocol:
• Places evidence-based practices in the context of national resources.
Where clinical trials specific to resource-constrained settings have
been conducted, associated protocols are applied (e.g. nephroblastoma,
acute lymphoblastic leukemia, and Burkitt lymphoma).
• Is organized in a consistent format, with each protocol including
subsections on screening, presenting signs and symptoms, pathology-
based diagnosis, staging, treatment, and long-term follow up.
• Specifies the minimal essential work-up required to yield accurate,
pathology-based diagnosis and inform management decision-
making within the treatment options available. At BCCOE, testing for
HER2 status is not routinely performed given limited availability of
HER2-targeted therapies such as trastuzumab.
• Reflects staging classification that is clinically relevant and in line
with treatment options. Three broad classifications/treatment
groups for breast cancer are: early, locally advanced and metastatic.
• Takes into account the currently limited availability of radiotherapy.
Mastectomy (with level I/II lymph node dissection) is prioritized as
surgical treatment of choice over lumpectomy.
• Allows flexibility to address socioeconomic and logistical challenges
seen in these settings. Weekly dosing of paclitaxel is employed
where possible, however every three weeks dosing is offered given
fewer barriers associated with the fewer hospital visits.
For more detailed reference, copies of individual protocols are available
upon request.
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2013, 95 (12.5 %) cancer patients had died. Cause of death
was documented as cancer-related for 24 (25.6 %), and un-
known for 66 (69.5 %). Thirty-six (37.9 %) patients died at
home or in the community while 45 (47.4 %) died during
admission at BCCOE or another facility.
Discussion
Patients served
Butaro Cancer Center of Excellence has begun to deliver
cancer services to a large number of patients in need in
Rwanda (Table 3). Patients come from across the country,
Table 3 Demographic and clinical characteristics of patients seen at BCCOE during first year
Characteristics Patients presenting for cancer evaluation/care in
year one (n = 1144)
Patients diagnosed with cancer
in year one (n = 759)
n % n %
Age 1144 100.00 759 100.00
<18 135 11.80 102 13.44
18–45 470 41.08 247 32.54
46–60 334 29.20 256 33.73
>60 205 17.92 154 20.29
Gender 1144 100.00 759 100.00
Male 355 31.03 240 31.62
Female 789 68.97 519 68.38
Residence Province 1144 100.01 759 100.00
Northern Province - within Burera District 168 14.69 67 8.83
Northern Province- OUTSIDE Burera District 226 19.76 136 17.92
Other Provinces within Rwanda 702 61.36 522 68.77
Outside Rwanda 13 1.14 11 1.45
Unknown or not documented 35 3.06 23 3.03
Type of referring facility 1144 100.00 759 100.00
Referral or District Hospital 735 64.25 549 72.33
Other type of facility (including outside Rwanda) 153 13.37 90 11.86
Not documented 256 22.38 120 15.81
Insurance Status 1144 100.00 750 98.82
Mutuelles 821 71.77 564 74.31
Other or not documented 323 28.23 186 24.51
HIV status at intake 1144 100.00 759 100.00
Positive 67 5.86 57 7.51
Negative 500 43.71 367 48.35
Unknown or not documented 577 50.43 335 44.14
Smoking history 1144 100.00 759 100.01
Current of previous 189 16.52 150 19.77
Never 645 56.38 471 62.06
Unknown or not documented 310 27.10 138 18.18






Unknown or not documented 256 33.73
aECOG: Eastern Cooperation Oncology Group [17]
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most residing in rural districts and covered by Mutuelles,
thus indicating delivery to our target vulnerable popula-
tions. The unprecedented patient volume reflects the great
need and highlights BCCOE’s service as a national referral
hospital for cancer care.
Cancers seen
Among adults, the most common diagnoses were breast
cancer (189, 28.8 %), cervical cancer (141, 21.5 %), and
non-Kaposi sarcoma skin cancer (46, 7.0 %). Among chil-
dren, nephroblastoma (28, 27.5 %), acute lymphoblastic
leukemia/ALL (25, 24.5 %), and Hodgkin lymphoma (10,
9.8 %) were the leading diagnoses (Table 4). Cancers seen
at BCCOE reflect some of the regional trends, such as the
two most common cancers being breast and cervical. In
its first year, BCCOE would have seen half of all breast
cancer cases expected to be diagnosed nationally based on
GLOBOCAN’s estimates of 576 new breast cancer diag-
noses annually in Rwanda [1], though the true national
incidence and prevalence is currently unknown given
robust registries to more accurately document cancer
cases continue to be under development. The leading
pediatric cancer at BCCOE was nephroblastoma. At
27 % of pediatric cancers, this proportion was compar-
able to sites in the region such as in Zambia [18],
though significantly higher than 5 % among pediatric
cancers in the United States [19]. The second most
prominent pediatric cancer, ALL, was similarly common
internationally [1, 19].
The distribution of cancers seen at BCCOE was influ-
enced by variation in clinical resources across facilities in
Rwanda, as well as patient selection. Prostate and gastric
cancers, among the top five cancers in the region [1] were
anecdotally less commonly seen at BCCOE than the
Table 4 Types of cancers diagnosed in patients enrolled at BCCOE during first year
Cancers only (n = 759)
n % n %
Cancer Type Adults (18 years or older) 657 100.0 Cancer Type Children (<18 years) 102 100.0
Breast cancer 189 28.8 Nephroblastoma 28 27.5
Cervical Cancer 141 21.5 ALLa 25 24.5
Non-Kaposi skin cancer 46 7.0 Hodgkin lymphoma 10 9.8
Head and neck cancer 38 5.8 Rhabdomyosarcoma 7 6.9
Colorectal cancer 26 4.0 Burkitt Lymphoma 5 4.9
Other Gynecological Malignancies 26 4.0 Osteosarcoma 5 4.9
CMLa 22 3.4 Head and neck cancer 4 3.9
Other Non Hodgkin’s lymphoma 21 3.2 Other Leukemias 4 3.9
Gastric cancer 21 3.2 Other Non Hodgkin’s lymphoma 3 2.9
Kaposi sarcoma 16 2.4 Other Bone Cancers 3 2.9
Prostate cancer 16 2.4 Kaposi’s sarcoma 2 2.0
Other GIa 14 2.1 Other Gynecological Malignancies 2 2.0
Hodgkin’s lymphoma 13 2.0 Breast cancer 1 1.0
Soft-tissue Sarcomas 12 1.8 CMLa 1 1.0
Other GUa 11 1.7 Metastatic (unknown primary) 1 1.0
Other solid cancers 9 1.4 Skin cancer 1 1.0
Other Leukemias 8 1.2
ALLa 7 1.1
Metastatic (unknown primary) 5 0.8
Multiple myeloma 5 0.8
Osteosarcoma 3 0.5
Unknown type 2 0.3
Rhabdomyosarcoma 2 0.3
Other Bone Cancers 2 0.3
Large B-cell lymphoma 1 0.2
Nephroblastoma 1 0.2
aCML chronic myeloid leukemia, Other GI other gastrointestinal cancers, Other GU other genitourinary cancers, ALL acute lymphoblastic leukemia
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national referral hospital CHUK, which has resident
endoscopists and urologists. Strengthening of the national
cancer registry will provide a more accurate epidemiologic
picture of cancers in Rwanda, though diagnostic capacity
is limited in much of the country so many patients remain
undiagnosed and therefore uncounted. In addition to teas-
ing out the role of diagnostic and referral bias, further
studies may be needed to explore region-specific risk fac-
tors for cancers.
Outcomes
It is too early to describe disease-specific clinical out-
comes, planned for the near future. Of note, however, of
the 95 documented deaths, that the majority (53, 55.8 %)
of patients die at home or while admitted at another fa-
cility makes discerning cause of death difficult and partly
explains the large number (66, 69.5 %) of deaths with
unknown cause.
Challenges and lessons learned
Documentation gaps
The current oncology EMR needs further development
but serves as a starting point. Many EMR systems for HIV
in resource-constrained settings have demonstrated posi-
tive impact [15, 16], however few if any published exam-
ples describe systems for cancer care. While data gaps
have to be addressed and clinical impact of BCCOE’s
EMR system to be assessed, we have used this system to
generate the presented data and routinely to support clin-
ical management and program development. EMR data
has, for instance, improved tracking of patients who miss
appointments and prioritization of protocol revisions.
While the initial phase of EMR development emphasized
data supporting management decisions and patient reten-
tion, the next phase aims to better capture disease-specific
outcomes, evaluate protocol adherence, and monitor treat-
ment toxicity.
Staff shortages
Unprecedented patient volume contributed to perpetual
staffing shortages, requiring periodic review. The initial
seven ward nurses increased to 26 as of August 2014,
corresponding to a nurse: inpatient ratio of 1:8. Despite
the higher patient volume, in-service training, and heavy
emotional toll of their work, oncology nurses are currently
paid the same as those in other departments. Temporary
relief has been achieved by increasing staff using personnel
allocated by RMOH and additional funding from partners.
However, strategies for compensation and professional
accreditation for nurses and doctors will be necessary to
sustain a cadre of oncology-skilled clinicians [8].
Butaro Cancer Center of Excellence does not have an on-
site gynecologist or pathologist, and has only intermittently
had a surgeon [13, 14]. While recruitment is in process and
longer-term local capacity is developed through in-country
post-graduate programs [8], discussions are underway for
BCCOE to serve as a national oncology rotation site for
post-graduate doctors. The stream of students and af-
filiated rotating faculty may mitigate staffing shortages
while presenting valuable opportunities for learning and
collaboration.
Access to radiotherapy
Over 50 % of cancer cases in LMICs countries are esti-
mated to require radiotherapy [20], yet Rwanda does not
have a radiotherapy facility. PIH sponsored an average of
15 patients a month to receive radiotherapy at Uganda’s
Mulago Hospital. Due to budget constraints, a commit-
tee of clinicians used institutional guidelines to select a
subset of eligible patients, mainly with curable cervical
and head and neck cancers. The average cost per patient
receiving a 6-week course of chemo-radiation for locally
advanced cervical cancer (includes transport, room and
board, and medical services) was USD 2800, amounting
to over USD 500,000 spent per year. Systematic study of
patient outcomes following referral for radiation at
Mulago is planned. Discussions are ongoing to build a
radiotherapy facility within the next 5 years— a critically-
needed investment to expand treatment options for
Rwandans.
Program expenses
The most significant costs in BCCOE’s program budget
were radiotherapy referrals, chemotherapy, and staff salar-
ies. Chemotherapy orders during BCCOE’s first year
amounted to USD 110,000 while clinical staff salaries
totaled USD 312,000. Though a substantial amount, fund-
ing can be within reach and costs significantly reduced
through partnerships. As examples, salaries for US-
licensed specialists supporting cancer care were subsi-
dized through part-time hospitalist work in the US.
Medications were sourced from accredited India-based
generic drug companies whose prices were three to five
times cheaper than European counterparts [21]. In
addition to these program-level strategies, it is our
hope that through advocacy and price negotiation, glo-
bal financing mechanisms for cancer care will become a
reality, as was accomplished for antiretroviral therapy.
Sustainability
The scale of BCCOE’s work and its funding can be attrib-
uted to the broad and invested collaborations supporting
it. While we currently have not yet enumerated the cost of
implementing BCCOE (an exercise that is currently in
process), approaches have been made to minimize costs
and facilitate sustainability of the program. RMOH’s en-
gagement and role in financing and shepherding partner-
ships has not only helped frame national priority, but has
Tapela et al. BMC Cancer  (2016) 16:237 Page 7 of 9
provided an avenue for continuation of services over the
long-term and their integration into the existing health in-
frastructure. Use of open-source data systems and of ro-
tating volunteer experts have also minimized costs. On a
global scale partners are participating in efforts with
World Health Organization and manufacturing compan-
ies geared toward lowering prices of chemotherapeutic
agents and improving access internationally.
Conclusion
Butaro Cancer Center of Excellence demonstrates that,
with partnerships and supports, complex cancer care
can be delivered in the most resource-constrained set-
tings and despite significant challenges. Key attributes
that have made BCCOE possible were: a) meaningful
partnerships emphasizing health systems strengthening,
b) innovative task- and infrastructure-shifting, c) strong
RMOH leadership coordinating efforts to embed ser-
vices within the public sector, and d) an equity-driven
agenda to service those most in need. This combination
is rare yet essential to expand desperately needed cancer
services globally. Looking forward, clinical outcomes will
be assessed such as long-term survival, retention and
treatment-related toxicity for specific cancers treated.
The developed EMR system will serve as a valuable plat-
form for this assessment. Finally, these partnerships con-
tinue to grow and support national efforts, including
periodic review of national protocols to reflect experi-
ence since 2012 and planning for an in-country radio-
therapy center.
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